metformin has been researched along with Leukemia, Myelomonocytic, Acute in 1 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Leukemia, Myelomonocytic, Acute: A pediatric acute myeloid leukemia involving both myeloid and monocytoid precursors. At least 20% of non-erythroid cells are of monocytic origin.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kawashima, I | 1 |
| Mitsumori, T | 1 |
| Nozaki, Y | 1 |
| Yamamoto, T | 1 |
| Shobu-Sueki, Y | 1 |
| Nakajima, K | 1 |
| Kirito, K | 1 |
1 other study available for metformin and Leukemia, Myelomonocytic, Acute
| Article | Year |
|---|---|
Negative regulation of the LKB1/AMPK pathway by ERK in human acute myeloid leukemia cells.
Topics: Adult; Aged; AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Antineoplastic Age | 2015 |